Know more

About cookies

What is a "cookie"?

A "cookie" is a piece of information, usually small and identified by a name, which may be sent to your browser by a website you are visiting. Your web browser will store it for a period of time, and send it back to the web server each time you log on again.

Different types of cookies are placed on the sites:

  • Cookies strictly necessary for the proper functioning of the site
  • Cookies deposited by third party sites to improve the interactivity of the site, to collect statistics

Learn more about cookies and how they work

The different types of cookies used on this site

Cookies strictly necessary for the site to function

These cookies allow the main services of the site to function optimally. You can technically block them using your browser settings but your experience on the site may be degraded.

Furthermore, you have the possibility of opposing the use of audience measurement tracers strictly necessary for the functioning and current administration of the website in the cookie management window accessible via the link located in the footer of the site.

Technical cookies

Name of the cookie


Shelf life

CAS and PHP session cookies

Login credentials, session security



Saving your cookie consent choices

12 months

Audience measurement cookies (AT Internet)

Name of the cookie


Shelf life


Trace the visitor's route in order to establish visit statistics.

13 months


Store the anonymous ID of the visitor who starts the first time he visits the site

13 months


Identify the numbers (unique identifiers of a site) seen by the visitor and store the visitor's identifiers.

13 months

About the AT Internet audience measurement tool :

AT Internet's audience measurement tool Analytics is deployed on this site in order to obtain information on visitors' navigation and to improve its use.

The French data protection authority (CNIL) has granted an exemption to AT Internet's Web Analytics cookie. This tool is thus exempt from the collection of the Internet user's consent with regard to the deposit of analytics cookies. However, you can refuse the deposit of these cookies via the cookie management panel.

Good to know:

  • The data collected are not cross-checked with other processing operations
  • The deposited cookie is only used to produce anonymous statistics
  • The cookie does not allow the user's navigation on other sites to be tracked.

Third party cookies to improve the interactivity of the site

This site relies on certain services provided by third parties which allow :

  • to offer interactive content;
  • improve usability and facilitate the sharing of content on social networks;
  • view videos and animated presentations directly on our website;
  • protect form entries from robots;
  • monitor the performance of the site.

These third parties will collect and use your browsing data for their own purposes.

How to accept or reject cookies

When you start browsing an eZpublish site, the appearance of the "cookies" banner allows you to accept or refuse all the cookies we use. This banner will be displayed as long as you have not made a choice, even if you are browsing on another page of the site.

You can change your choices at any time by clicking on the "Cookie Management" link.

You can manage these cookies in your browser. Here are the procedures to follow: Firefox; Chrome; Explorer; Safari; Opera

For more information about the cookies we use, you can contact INRAE's Data Protection Officer by email at or by post at :


24, chemin de Borde Rouge -Auzeville - CS52627 31326 Castanet Tolosan cedex - France

Last update: May 2021

Menu Logo Principal Oniris

Home page

Epidemiological modelling and its use to manage COVID-19

Insights into mechanistic models, by the DYNAMO team

Over the next few weeks, we will present some key elements of epidemiological modelling through short educational articles. These articles will help you to better understand and decipher the assumptions underlying the epidemiological models that are currently widely used, and how these assumptions can impact predictions regarding the spread of pathogens, particularly SARS-CoV-2. The objective is to discover the advantages and limitations of mechanistic modelling, an approach that is at the core of the DYNAMO team's work. The examples of models will be inspired by models used in crisis, but sometimes simplified to make them accessible.

#6 – Why represent the heterogeneity of infected individuals in the model ? (2/2)

Other factors explain why the models are sometimes made more complex, particularly with regard to infected individuals. First of all, the diagrams of epidemiological models are the result of discussions between people with different profiles and disciplines: epidemiology, mathematics, computer science, but also virology, medicine, management, etc. These diagrams therefore result from a compromise between parsimony (i.e. the fewest possible parameters) and realism (associated with better readability of the model by non-modellers). To illustrate this, we have decomposed shedder individuals according to the level of excretion (pink vs. red), and the level of disease severity (light or dark blue). We also considered the level of symptom onset (see figure below). Compared to the diagram in article #5, this better reflects what experts in the field know about the infection and the disease. It also makes it possible to adjust the parameters (contacts, shedding levels; see table below) and the transitions according to the health states. Thus, this scheme considers that only individuals with severe symptoms (Iss) will go to hospital (H) or even to intensive care units (ICU), and are therefore at risk of dying from COVID-19.

Schéma de modélisation avec différents états I ("infecté")

Epidemiological model considering as health states: susceptible (S), latent non-shedding infected (E), incubating shedding infected (Ip), asymptomatic (Ia), pauci-symptomatic (Ips), moderately symptomatic (Ims), with severe symptoms (Iss), in hospital (H), in intensive care unit (ICU), cured (R), and dead (M). The strength of infection (λ) takes into account the difference in the contribution of shedding infected persons to new infections (adapted from Di Domenico et al. report).

Table of model parameters (adapted from Di Domenico et al. report).



Selected values


Basal transmission rate (day-1)



Multiplying factor for reducing the excretion of Ip, Ia, Ips



Multiplying factor to reduce the contact of the Iss, H, ICU



Average latency time (days)



Average duration of the state Ip (days)


[pa, pps, pms, pss]

Probability of being Ia, Ips, Ims or Iss (sum = 1)

[0.3, 0.2, 0.3, 0.2]


Average duration of states Ia, Ips, Ims, Iss (days)



Probability of admission to an intensive care unit due to severe symptoms



Average duration at hospital (days)



Proportion of H that recover



Average duration in intensive care unit (days)



Proportion of ICU that recover


These values give a basic reproductive rate R = 3.3 without control.

This type of model makes it possible, for example, to compare a situation without any control with a situation assuming a lockdown of the general population from March 16 to May 11, then a social distancing from May 11 to May 26 (end date of the predictions in the figures below). It is possible to look not only at the number of cumulative deaths (these observations being available and enabling the model to be calibrated), but also at the number of people in intensive care units. Thus, if the model is correctly defined and calibrated, it is possible to identify when to intervene to avoid exceeding hospital capacity. We will detail these aspects in a next article.

Nombre de décès cumulés par jour avec (en noir) et sans (en rouge) confinement
Nombre de personnes en soins intensifs par jour avec (en noir) et sans (en rouge) confinement

Predictions of the model in terms of cumulative number of deaths (top) and number of people in intensive care units (bottom), assuming an introduction of the virus on January 7 in the general French population, and assuming that lockdown reduces contacts by 90%, while social distancing reduces them by 50%. The observation data (cross) correspond to March 16, April 5, May 11 and May 26.

Such models can also help to test interventions that are targeted (e.g., only symptomatic individuals are isolated, with a longer detection time for the pauci-symptomatic), or that would not apply equally to all groups (e.g., social distancing requested from all, but less applied by the asymptomatic). Article #8 will continue this discussion, focusing more specifically on targeted management measures.